Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $90,265.40 in Stock

Key Points

• CEO Berndt Modig sold 2,291 Pharvaris shares at an average price of $39.40, generating $90,265.40. His remaining 128,334-share stake is valued at roughly $5.06 million, a 1.75% reduction.
• Pharvaris shares fell 1.6% to $38.25, while the company reported a quarterly loss of $0.81 per share, missing analysts’ $0.75-loss estimate.
• Despite recent insider selling, analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target near $60; institutional investors also increased several positions in the second quarter.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 2,291 shares of Pharvaris stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $39.40, for a total value of $90,265.40. Following the completion of the transaction, the chief executive officer owned 128,334 shares in the company, valued at $5,056,359.60. This trade represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Berndt Modig also recently made the following trade(s):

• On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84.

Pharvaris Trading Down 1.6%

Shares of NASDAQ:PHVS traded down $0.61 during trading on Tuesday, reaching $38.25. The stock had a trading volume of 1,020,979 shares, compared to its average volume of 398,337. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25. The company has a market capitalization of $2.50 billion, a P/E ratio of -12.54 and a beta of -2.33. The firm's 50-day simple moving average is $35.20 and its 200 day simple moving average is $31.49.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Equities research analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in shares of Pharvaris in the second quarter valued at about $1,143,000. Amundi grew its stake in Pharvaris by 61.4% during the 2nd quarter. Amundi now owns 49,944 shares of the company's stock valued at $1,727,000 after acquiring an additional 18,992 shares in the last quarter. Moore Capital Management LP acquired a new stake in Pharvaris in the 2nd quarter valued at about $1,522,000. Alyeska Investment Group L.P. lifted its stake in Pharvaris by 225.5% in the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock worth $14,068,000 after purchasing an additional 281,829 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after purchasing an additional 274,034 shares in the last quarter.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ shares have gained about 10% over the past month after Phase 3 results showed that the extended-release formulation of deucrictibant reduced hereditary angioedema attacks by 83%. The data support the company’s plans to pursue regulatory submissions in 2027 and strengthen the outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst price-target expectations have improved. The reported consensus target was raised approximately 20% to $59.77, while RBC recently increased its target to $62 and maintained an outperform rating. The broader analyst view remains favorable, with a consensus “Moderate Buy” rating and an average target near $60. Pharvaris NV consensus price target raised 20.08% to $59.77
• Neutral Sentiment: Institutional ownership trends have been supportive, with investors including BlackRock and Alyeska Investment Group building positions. This may provide additional demand, although the purchases reflect earlier reporting periods rather than a new catalyst.
• Negative Sentiment: Several insiders recently sold shares. Director Anne Lesage sold 30,000 shares for approximately $1.15 million, while CEO Berndt Modig sold 2,291 shares for about $90,000 and President Peng Lu sold 15,000 shares for roughly $602,000. Lu’s transaction was made to cover tax withholding on vested equity awards, which reduces its negative signal, but the volume of insider selling could still weigh on sentiment. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of recent analyst reports. Leerink Partners upped their price target on Pharvaris from $50.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research report on Wednesday, September 9th. Citigroup restated a "market outperform" rating on shares of Pharvaris in a research note on Wednesday, September 9th. Wells Fargo & Company upped their target price on Pharvaris from $55.00 to $65.00 and gave the company an "overweight" rating in a research report on Wednesday, September 9th. Finally, Morgan Stanley increased their price target on Pharvaris from $46.00 to $62.00 and gave the company an "overweight" rating in a research note on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pharvaris presently has a consensus rating of "Moderate Buy" and a consensus price target of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.